Hybrid inhalable microparticles for dual controlled release of levofloxacin and DNase: physicochemical characterization and in vivo targeted delivery to the lungs
- Autores
- Islan, Germán Abel; Ruiz, María Esperanza; Morales, Juan Francisco; Sbaraglini, María Laura; Enrique, Andrea Verónica; Burton, Gerardo; Talevi, Alan; Bruno Blanch, Luis Enrique; Castro, Guillermo Raúl
- Año de publicación
- 2017
- Idioma
- inglés
- Tipo de recurso
- artículo
- Estado
- versión publicada
- Descripción
- Current medical treatments against recurrent pulmonary infections caused by Pseudomonas aeruginosa, such as cystic fibrosis (CF) disorder, involve the administration of inhalable antibiotics. The main challenge is, however, the eradication of microbial biofilms immersed in dense mucus that requires high and recurrent antibiotic doses. Accordingly, the development of novel drug delivery systems capable of providing local and controlled drug release in the lungs is a key factor to improve the therapeutic outcome of such therapeutic molecules. Inhalable hybrid carriers were prepared by co-precipitation of CaCO₃ in the presence of alginate and the resulting microparticles were treated with alginate lyase (AL) in order to modify their porosity and enhance the drug loading. The hybrid microparticles were loaded with DNase (mucolytic agent) and levofloxacin (LV, wide-spectrum antibiotic) in the range of 20–40% for LV and 28–67% for DNase, depending on the AL treatment. In vitro studies demonstrated that microparticles were able to control the DNase release for 24 h, while 30–50% of LV was released in 3 days. The morphological characterization was performed by optical, fluorescence and scanning electron microscopies, showing a narrow size distribution (5 μm). FTIR, XRD, DSC and nitrogen adsorption isotherm studies revealed the presence of the drugs in a non-crystalline state. A microcidal effect of microparticles was found on P. aeruginosa in agar plates and corroborated by Live/Dead kit and TEM observations. Finally, to study whether the microparticles improved the localization of LV in the lungs, in vivo studies were performed by pulmonary administration of microparticles to healthy mice via nebulization and dry powder inhalation, followed by the quantification of LV in lung tissue. The results showed that microparticles loaded with LV delivered the antibiotic at least 3 times more efficiently than free LV. The developed system opens the gateway to new drug delivery systems that may provide enhanced therapeutic solutions against bacterial infections and in particular as a potential tool in CF pathology.
Centro de Investigación y Desarrollo en Fermentaciones Industriales
Laboratorio de Investigación y Desarrollo de Bioactivos - Materia
-
Ciencias Exactas
Biología
Pseudomonas aeruginosa
cystic fibrosis
antibiotics - Nivel de accesibilidad
- acceso abierto
- Condiciones de uso
- http://creativecommons.org/licenses/by/4.0/
- Repositorio
- Institución
- Universidad Nacional de La Plata
- OAI Identificador
- oai:sedici.unlp.edu.ar:10915/147827
Ver los metadatos del registro completo
id |
SEDICI_b3f22bf72e659a5d58925712d03fce1b |
---|---|
oai_identifier_str |
oai:sedici.unlp.edu.ar:10915/147827 |
network_acronym_str |
SEDICI |
repository_id_str |
1329 |
network_name_str |
SEDICI (UNLP) |
spelling |
Hybrid inhalable microparticles for dual controlled release of levofloxacin and DNase: physicochemical characterization and in vivo targeted delivery to the lungsIslan, Germán AbelRuiz, María EsperanzaMorales, Juan FranciscoSbaraglini, María LauraEnrique, Andrea VerónicaBurton, GerardoTalevi, AlanBruno Blanch, Luis EnriqueCastro, Guillermo RaúlCiencias ExactasBiologíaPseudomonas aeruginosacystic fibrosisantibioticsCurrent medical treatments against recurrent pulmonary infections caused by <i>Pseudomonas aeruginosa</i>, such as cystic fibrosis (CF) disorder, involve the administration of inhalable antibiotics. The main challenge is, however, the eradication of microbial biofilms immersed in dense mucus that requires high and recurrent antibiotic doses. Accordingly, the development of novel drug delivery systems capable of providing local and controlled drug release in the lungs is a key factor to improve the therapeutic outcome of such therapeutic molecules. Inhalable hybrid carriers were prepared by co-precipitation of CaCO₃ in the presence of alginate and the resulting microparticles were treated with alginate lyase (AL) in order to modify their porosity and enhance the drug loading. The hybrid microparticles were loaded with DNase (mucolytic agent) and levofloxacin (LV, wide-spectrum antibiotic) in the range of 20–40% for LV and 28–67% for DNase, depending on the AL treatment. <i>In vitro</i> studies demonstrated that microparticles were able to control the DNase release for 24 h, while 30–50% of LV was released in 3 days. The morphological characterization was performed by optical, fluorescence and scanning electron microscopies, showing a narrow size distribution (5 μm). FTIR, XRD, DSC and nitrogen adsorption isotherm studies revealed the presence of the drugs in a non-crystalline state. A microcidal effect of microparticles was found on <i>P. aeruginosa</i> in agar plates and corroborated by Live/Dead kit and TEM observations. Finally, to study whether the microparticles improved the localization of LV in the lungs, <i>in vivo</i> studies were performed by pulmonary administration of microparticles to healthy mice via nebulization and dry powder inhalation, followed by the quantification of LV in lung tissue. The results showed that microparticles loaded with LV delivered the antibiotic at least 3 times more efficiently than free LV. The developed system opens the gateway to new drug delivery systems that may provide enhanced therapeutic solutions against bacterial infections and in particular as a potential tool in CF pathology.Centro de Investigación y Desarrollo en Fermentaciones IndustrialesLaboratorio de Investigación y Desarrollo de Bioactivos2017info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionArticulohttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdf3132-3144http://sedici.unlp.edu.ar/handle/10915/147827enginfo:eu-repo/semantics/altIdentifier/issn/2050-750Xinfo:eu-repo/semantics/altIdentifier/issn/2050-7518info:eu-repo/semantics/altIdentifier/doi/10.1039/c6tb03366kinfo:eu-repo/semantics/openAccesshttp://creativecommons.org/licenses/by/4.0/Creative Commons Attribution 4.0 International (CC BY 4.0)reponame:SEDICI (UNLP)instname:Universidad Nacional de La Platainstacron:UNLP2025-10-15T11:29:41Zoai:sedici.unlp.edu.ar:10915/147827Institucionalhttp://sedici.unlp.edu.ar/Universidad públicaNo correspondehttp://sedici.unlp.edu.ar/oai/snrdalira@sedici.unlp.edu.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:13292025-10-15 11:29:41.889SEDICI (UNLP) - Universidad Nacional de La Platafalse |
dc.title.none.fl_str_mv |
Hybrid inhalable microparticles for dual controlled release of levofloxacin and DNase: physicochemical characterization and in vivo targeted delivery to the lungs |
title |
Hybrid inhalable microparticles for dual controlled release of levofloxacin and DNase: physicochemical characterization and in vivo targeted delivery to the lungs |
spellingShingle |
Hybrid inhalable microparticles for dual controlled release of levofloxacin and DNase: physicochemical characterization and in vivo targeted delivery to the lungs Islan, Germán Abel Ciencias Exactas Biología Pseudomonas aeruginosa cystic fibrosis antibiotics |
title_short |
Hybrid inhalable microparticles for dual controlled release of levofloxacin and DNase: physicochemical characterization and in vivo targeted delivery to the lungs |
title_full |
Hybrid inhalable microparticles for dual controlled release of levofloxacin and DNase: physicochemical characterization and in vivo targeted delivery to the lungs |
title_fullStr |
Hybrid inhalable microparticles for dual controlled release of levofloxacin and DNase: physicochemical characterization and in vivo targeted delivery to the lungs |
title_full_unstemmed |
Hybrid inhalable microparticles for dual controlled release of levofloxacin and DNase: physicochemical characterization and in vivo targeted delivery to the lungs |
title_sort |
Hybrid inhalable microparticles for dual controlled release of levofloxacin and DNase: physicochemical characterization and in vivo targeted delivery to the lungs |
dc.creator.none.fl_str_mv |
Islan, Germán Abel Ruiz, María Esperanza Morales, Juan Francisco Sbaraglini, María Laura Enrique, Andrea Verónica Burton, Gerardo Talevi, Alan Bruno Blanch, Luis Enrique Castro, Guillermo Raúl |
author |
Islan, Germán Abel |
author_facet |
Islan, Germán Abel Ruiz, María Esperanza Morales, Juan Francisco Sbaraglini, María Laura Enrique, Andrea Verónica Burton, Gerardo Talevi, Alan Bruno Blanch, Luis Enrique Castro, Guillermo Raúl |
author_role |
author |
author2 |
Ruiz, María Esperanza Morales, Juan Francisco Sbaraglini, María Laura Enrique, Andrea Verónica Burton, Gerardo Talevi, Alan Bruno Blanch, Luis Enrique Castro, Guillermo Raúl |
author2_role |
author author author author author author author author |
dc.subject.none.fl_str_mv |
Ciencias Exactas Biología Pseudomonas aeruginosa cystic fibrosis antibiotics |
topic |
Ciencias Exactas Biología Pseudomonas aeruginosa cystic fibrosis antibiotics |
dc.description.none.fl_txt_mv |
Current medical treatments against recurrent pulmonary infections caused by <i>Pseudomonas aeruginosa</i>, such as cystic fibrosis (CF) disorder, involve the administration of inhalable antibiotics. The main challenge is, however, the eradication of microbial biofilms immersed in dense mucus that requires high and recurrent antibiotic doses. Accordingly, the development of novel drug delivery systems capable of providing local and controlled drug release in the lungs is a key factor to improve the therapeutic outcome of such therapeutic molecules. Inhalable hybrid carriers were prepared by co-precipitation of CaCO₃ in the presence of alginate and the resulting microparticles were treated with alginate lyase (AL) in order to modify their porosity and enhance the drug loading. The hybrid microparticles were loaded with DNase (mucolytic agent) and levofloxacin (LV, wide-spectrum antibiotic) in the range of 20–40% for LV and 28–67% for DNase, depending on the AL treatment. <i>In vitro</i> studies demonstrated that microparticles were able to control the DNase release for 24 h, while 30–50% of LV was released in 3 days. The morphological characterization was performed by optical, fluorescence and scanning electron microscopies, showing a narrow size distribution (5 μm). FTIR, XRD, DSC and nitrogen adsorption isotherm studies revealed the presence of the drugs in a non-crystalline state. A microcidal effect of microparticles was found on <i>P. aeruginosa</i> in agar plates and corroborated by Live/Dead kit and TEM observations. Finally, to study whether the microparticles improved the localization of LV in the lungs, <i>in vivo</i> studies were performed by pulmonary administration of microparticles to healthy mice via nebulization and dry powder inhalation, followed by the quantification of LV in lung tissue. The results showed that microparticles loaded with LV delivered the antibiotic at least 3 times more efficiently than free LV. The developed system opens the gateway to new drug delivery systems that may provide enhanced therapeutic solutions against bacterial infections and in particular as a potential tool in CF pathology. Centro de Investigación y Desarrollo en Fermentaciones Industriales Laboratorio de Investigación y Desarrollo de Bioactivos |
description |
Current medical treatments against recurrent pulmonary infections caused by <i>Pseudomonas aeruginosa</i>, such as cystic fibrosis (CF) disorder, involve the administration of inhalable antibiotics. The main challenge is, however, the eradication of microbial biofilms immersed in dense mucus that requires high and recurrent antibiotic doses. Accordingly, the development of novel drug delivery systems capable of providing local and controlled drug release in the lungs is a key factor to improve the therapeutic outcome of such therapeutic molecules. Inhalable hybrid carriers were prepared by co-precipitation of CaCO₃ in the presence of alginate and the resulting microparticles were treated with alginate lyase (AL) in order to modify their porosity and enhance the drug loading. The hybrid microparticles were loaded with DNase (mucolytic agent) and levofloxacin (LV, wide-spectrum antibiotic) in the range of 20–40% for LV and 28–67% for DNase, depending on the AL treatment. <i>In vitro</i> studies demonstrated that microparticles were able to control the DNase release for 24 h, while 30–50% of LV was released in 3 days. The morphological characterization was performed by optical, fluorescence and scanning electron microscopies, showing a narrow size distribution (5 μm). FTIR, XRD, DSC and nitrogen adsorption isotherm studies revealed the presence of the drugs in a non-crystalline state. A microcidal effect of microparticles was found on <i>P. aeruginosa</i> in agar plates and corroborated by Live/Dead kit and TEM observations. Finally, to study whether the microparticles improved the localization of LV in the lungs, <i>in vivo</i> studies were performed by pulmonary administration of microparticles to healthy mice via nebulization and dry powder inhalation, followed by the quantification of LV in lung tissue. The results showed that microparticles loaded with LV delivered the antibiotic at least 3 times more efficiently than free LV. The developed system opens the gateway to new drug delivery systems that may provide enhanced therapeutic solutions against bacterial infections and in particular as a potential tool in CF pathology. |
publishDate |
2017 |
dc.date.none.fl_str_mv |
2017 |
dc.type.none.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion Articulo http://purl.org/coar/resource_type/c_6501 info:ar-repo/semantics/articulo |
format |
article |
status_str |
publishedVersion |
dc.identifier.none.fl_str_mv |
http://sedici.unlp.edu.ar/handle/10915/147827 |
url |
http://sedici.unlp.edu.ar/handle/10915/147827 |
dc.language.none.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
info:eu-repo/semantics/altIdentifier/issn/2050-750X info:eu-repo/semantics/altIdentifier/issn/2050-7518 info:eu-repo/semantics/altIdentifier/doi/10.1039/c6tb03366k |
dc.rights.none.fl_str_mv |
info:eu-repo/semantics/openAccess http://creativecommons.org/licenses/by/4.0/ Creative Commons Attribution 4.0 International (CC BY 4.0) |
eu_rights_str_mv |
openAccess |
rights_invalid_str_mv |
http://creativecommons.org/licenses/by/4.0/ Creative Commons Attribution 4.0 International (CC BY 4.0) |
dc.format.none.fl_str_mv |
application/pdf 3132-3144 |
dc.source.none.fl_str_mv |
reponame:SEDICI (UNLP) instname:Universidad Nacional de La Plata instacron:UNLP |
reponame_str |
SEDICI (UNLP) |
collection |
SEDICI (UNLP) |
instname_str |
Universidad Nacional de La Plata |
instacron_str |
UNLP |
institution |
UNLP |
repository.name.fl_str_mv |
SEDICI (UNLP) - Universidad Nacional de La Plata |
repository.mail.fl_str_mv |
alira@sedici.unlp.edu.ar |
_version_ |
1846064336824434688 |
score |
13.22299 |